Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Celltrion, Inc.

Latest From Celltrion, Inc.

Coronavirus Update: BioNTech And Fosun Launch Vaccine Trial In China

The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.

Coronavirus COVID-19 Vaccines

WHO Prequalifies More Biosimilars

The World Health Organization has recently added further biosimilar versions of trastuzumab to its list of prequalified products, along with Roche’s original trastuzumab and rituximab brands, Herceptin and MabThera/Rituxan.

Biosimilars Regulation

Takeda Raises Profit Forecast After 'Pandemic-Resistant' Q1

Japan’s largest pharma company says it has seen no impact on its financial results so far from the coronavirus pandemic, with continuing growth for mainstay drugs, and raises its profit forecasts for the fiscal year on favorable one-off factors.

Commercial Sales & Earnings

Coronavirus Update: Will Moderna Really Demand Premium Price For COVID Vaccine?

There are reports that the US biotech is considering pricing its as-yet-unapproved mRNA-1273 at $25-30 a dose, a price which would double as both a prime and boost dose would be administered.

Coronavirus COVID-19 Vaccines
See All

Company Information

UsernamePublicRestriction

Register